[Long-term drug treatment of chronic polyarthritis: current status and perspectives].
The therapeutic repertoire for the treatment of rheumatoid arthritis has been expanded to new disease-modifying antirheumatic drugs (DMARDs), like Auranofine, Sulfasalazine, and Methotrexate. Rheumatoid arthritis is not only a highly disabling disease but is now recognized to be related with increased mortality. Therefore, the aim of therapeutic strategies is the early induction of remission. The strategy for treatment of rheumatoid arthritis should be based on an analysis of the individual risk of a patient to develop severe illness. A concept of "risk-oriented DMARD-therapy" of rheumatoid arthritis is proposed.
Abteilung Rheumatologie, Medizinische Hochschule Hannover, BRD.
J
J
Wollenhaupt
H E
HE
Langer
D000700:Analgesics / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans
D000700:Analgesics; D000893:Anti-Inflammatory Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D005938:Glucocorticoids
Medikamentöse Langzeitbehandlung der chronischen Polyarthritis: Aktueller Stand und Perspektiven.